![]() ![]() Encore: DREAMM-2: Single-Agent Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma Refractory to Proteasome Inhibitors, Immunomodulatory Agents, and Refractory and/or Intolerant to Anti-CD38 mAbs ħ. ![]() ![]() DREAMM-2: Single-Agent Belantamab Mafodotin in Patients With RRMM–Outcomes by Prior Therapies Ħ. Safety and Tolerability of Single-Agent Belantamab Mafodotin in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma: Pooled Data From DREAMM-1 and DREAMM-2 ĥ. Encore: DREAMM-1: Patient Perspectives From the First-in-Human Study of Single-Agent Belantamab Mafodotin for Relapsed/Refractory Multiple Myeloma (RRMM) Ĥ. Retrospective Analyses of SoC and Treatment Patterns Among Patients with RRMM in Europe ģ. Estimating the Number of US Patients With Multiple Myeloma at Different Lines of Treatment Ģ. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |